Sandwich, United Kingdom

Michael Westby

USPTO Granted Patents = 5 

 

Average Co-Inventor Count = 3.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Location History:

  • Sandwich, GB (2021 - 2022)
  • Kent, GB (2023)

Company Filing History:


Years Active: 2021-2025

Loading Chart...
Loading Chart...
5 patents (USPTO):Explore Patents

Title: Michael Westby: Innovator in Therapeutic Compounds

Introduction

Michael Westby is a notable inventor based in Sandwich, GB. He has made significant contributions to the field of therapeutic compounds, holding a total of 5 patents. His work focuses on linking immune responses to specific therapeutic targets, particularly in the treatment of cancer and infectious diseases.

Latest Patents

Westby's latest patents include innovative compounds designed to enhance immune responses. One of his inventions relates to novel compounds that can link an immune response to a defined therapeutic target, which can be utilized in treating cancer and infectious diseases. Another patent focuses on compounds that link an immune response to pathogens, aimed at addressing diseases or disorders caused by infective agents. Both patents also cover the compositions containing these compounds, the processes for their preparation, and the novel intermediates used in these processes.

Career Highlights

Throughout his career, Michael Westby has worked with various organizations, including Centauri Therapeutics Limited. His expertise in developing therapeutic compounds has positioned him as a key figure in the field of immunology and therapeutic innovation.

Collaborations

Westby has collaborated with professionals such as Melanie Glossop and Christine Watson, contributing to the advancement of therapeutic research and development.

Conclusion

Michael Westby is a distinguished inventor whose work in therapeutic compounds has the potential to significantly impact the treatment of various diseases. His innovative patents and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…